EUVIMEDSkopri EUVIMED
Crossref

Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents

Sazan Haji Ali, Derya Osmaniye, Begüm Nurpelin Sağlık, Serkan Levent iD, Yusuf Özkay, Zafer Asım Kaplancıklı

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14246 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2023. Written by Sazan Haji Ali and 5 co-authors. Institution: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hawler Medical University, Erbil, Iraq. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Cited 4 times so far (Crossref); 35 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

As lung cancer was placed foremost part among other types of cancer in terms of mortality. Recent researches are widely focused on developing multi‐targeted and site‐specific targeted drug designs. In the present study, we designed and developed a series of quinoxaline pharmacophore derivatives as active EGFR inhibitors for the treatment of non‐small cell lung cancer. The compounds were synthesized through a condensation reaction between hexane‐3,4‐dione and methyl 3,4‐diaminobenzoate as a first step. Their structures were confirmed by 1 H‐NMR, 13 C‐NMR, and HRMS spectroscopic methods. Cytotoxicity (MTT) were applied to determine anticancer activity of the compounds against breast (MCF7), fibroblast (NIH3 T3), and lung (A549) cell lines as EGFR inhibitors. Doxorubicin was used as a reference agent, compound 4i exhibited a significant effect among other derivatives with IC 50 = 3.902 ± 0.098 μM value against A549 cell line. The docking study showed that the best position on EGFR receptor could be observed with 4i . From the obtained evaluations of the designed series, compound 4i was a promising agent as EGFR inhibitor for further investigation and evaluation studies in the future.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipQuinoxalinesCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsDrug DesignCell Line, TumorProtein Kinase Inhibitors

Author keywords

EGFR inhibitorscytotoxicitydocking studylung carcinomaquinoxaline

Substances

QuinoxalinesAntineoplastic AgentsErbB ReceptorsProtein Kinase Inhibitors

Authors and institutions

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.
  • Central Research Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey.

ORCID profiles: Serkan Levent

Cite

APA

Ali, S. H., Osmaniye, D., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2023). Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14246

Vancouver

Ali SH, Osmaniye D, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14246

BibTeX
@article{Ali2023,
  author = {Ali, Sazan Haji and Osmaniye, Derya and Sağlık, Begüm Nurpelin and Levent, Serkan and Özkay, Yusuf and Kaplancıklı, Zafer Asım},
  title = {Design, synthesis, and molecular docking studies of novel quinoxaline derivatives as anticancer agents},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14246}
}
Start for free →